Results 1 to 10 of about 8,860 (153)

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir [PDF]

Drug and Alcohol Dependence, 2007
Opioid addiction and HIV disease frequently co-occur. Adverse drug interactions have been reported between methadone and some HIV medications, but less is known about interactions between buprenorphine, an opioid partial agonist used to treat opioid dependence, and HIV therapeutics.
Richard Difrancesco, Qing Ma, Petrie M Rainey   +2 more
exaly   +3 more sources

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS

Pharmaceutics, 2020
Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS.
Javed Ali, Sabna Kotta, Bushra Nabi
exaly   +3 more sources

Successful endourological treatment for a rare case of atazanavir‐induced urinary stones [PDF]

IJU Case Reports
Introduction Atazanavir, an anti‐HIV drug, induces urinary stone formation. We herein report a case of atazanavir‐induced bilateral ureteral stones treated with endourological procedures.
Takehiro Nakamura, Ryoji Takazawa, Yosuke Umino   +2 more
doaj   +2 more sources

Atazanavir nephrotoxicity [PDF]

Clinical Kidney Journal, 2015
Atazanavir is commonly used as one of the key drugs in combination antiretroviral therapy for human immunodeficiency virus (HIV). However, atazanavir has the potential to yield its crystalline precipitation in urine and renal interstitial tissues, leading to crystalluria, urolithiasis, acute kidney injury (AKI) or chronic kidney disease (CKD).
Hara, Masaki, Suganuma, Akihiko, Yanagisawa, Naoki, Imamura, Akifumi, Hishima, Tsunekazu, Ando, Minoru   +5 more
openaire   +2 more sources

Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load

Brazilian Journal of Infectious Diseases, 2013
Objective: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia).
Ana Júlia Luz, Júlia Poeta, Rafael Linden, Marina Venzon Antunes, Luiza Isola Caminha, Eduardo Sprinz   +5 more
doaj   +3 more sources

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
BACKGROUND: Serum bilirubin is inversely associated with cardiovascular risk. Atazanavir, an HIV protease inhibitor that competitively inhibits bilirubin conjugation, provides a unique opportunity to examine whether selectively increasing bilirubin is ...
Michael Li, Walter W. Chan, Stephen D. Zucker   +2 more
doaj   +1 more source

Atazanavir

Reactions Weekly, 2006
europepmc   +5 more sources

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

AIDS Research and Treatment, 2015
Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients ...
Catherine Orrell, Franco Felizarta, André Nell, Thomas N. Kakuda, Ludo Lavreys, Steven Nijs, Lotke Tambuyzer, Rodica Van Solingen-Ristea, Frank L. Tomaka   +8 more
doaj   +1 more source

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

BMC Infectious Diseases, 2017
Background Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.
Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N. Burchell, Ahmed M. Bayoumi, Julio S. G. Montaner, Mona Loutfy, Marina B. Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S. Hogg, Janet Raboud, The Canadian Observational Cohort (CANOC) collaboration   +14 more
doaj   +1 more source

Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method

Разработка и регистрация лекарственных средств, 2020
Introduction. HIV infection is one of the most relevant diseases from a medical, epidemiological and social point of view. Timely diagnosis, detection and control of the disease, adequate prescription of antiretroviral therapy can sufficiently reduce the
T. N. Komarov, I. E. Shohin, O. A. Miskiv, D. S. Bogdanova, A. V. Aleshina, Yu. V. Medvedev, N. S. Bagaeva   +6 more
doaj   +1 more source